ENTO Stock Summary and Trading Ideas (Entero Therapeutics | NASDAQ:ENTO)

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Entero Therapeutics trades on the NASDAQ stock market under the symbol ENTO.

As of December 12, 2024, ENTO stock price climbed to $0.63 with 414,954 million shares trading.

ENTO has a beta of 3.14, meaning it tends to be more sensitive to market movements. ENTO has a correlation of 0.04 to the broad based SPY ETF.

ENTO has a market cap of $2.98 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that ENTO belongs to (by Net Assets): VXF.

ENTO support price is $.52 and resistance is $.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTO shares will trade within this expected range on the day.